You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥-B(2142.HK)大漲13% 獲里昂看高至17.2港元
格隆匯 01-14 15:59
格隆匯1月14日丨和鉑醫藥-B(2142.HK)今日大肆反彈,盤中一度漲12.96%至9.5港元,市值73億港元。中信里昂發研報稱,和鉑醫藥是一家科研實力強勁,並具豐富臨牀開發經驗的創新型生物技術公司。公司通過世界一流的專有抗體發現平台,專注於免疫性疾病及腫瘤適應症的生物新藥研發。中信里昂預計,公司的核心資產巴託利單抗(HBM9161)、特那西普(HBM9036)和HBM4003,將從2023年開始陸續獲批上市,2024年開始實現盈利,到2030年利潤增長5倍。三款核心資產在2030年預計銷售峯值分別為75.42億元/2.95億元/24.66億元。給予和鉑醫藥-B“買入”評級,按照DCF測算目標價格為17.20港元,2024年PE為25.6x,PS為3.7x。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account